Vir Biotechnology advances hepatitis delta program and cash runway

Vir Biotechnology ( (VIR) ) has provided an update.

On January 12, 2026, Vir Biotechnology reported updated positive Phase 2 SOLSTICE data in chronic hepatitis delta showing that combination therapy with tobevibart and elebsiran achieved undetectable HDV RNA in 88% of evaluable participants at Week 96, with a favorable safety profile and stronger viral suppression than tobevibart alone, reinforcing the potential of this regimen as a future standard of care. The company outlined progress in its registrational ECLIPSE Phase 3 program in chronic hepatitis delta, highlighted upcoming presentations of Phase 1 data for PSMA-targeted T-cell engager VIR-5500 in metastatic castration-resistant prostate cancer at a major oncology meeting, and noted continued advancement of its broader PRO-XTEN oncology portfolio, while disclosing an unaudited year-end 2025 cash and investment balance of about $781 million and an extended cash runway into the fourth quarter of 2027, supported by a regional licensing deal with Norgine and disciplined spending.

The most recent analyst rating on (VIR) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Vir Biotechnology stock, see the VIR Stock Forecast page.

Spark’s Take on VIR Stock

According to Spark, TipRanks’ AI Analyst, VIR is a Neutral.

Vir Biotechnology’s overall stock score is primarily impacted by its financial performance challenges, including declining revenues and profitability issues. While the technical analysis and recent corporate events provide some positive signals, the negative valuation metrics and ongoing financial losses weigh heavily on the score.

To see Spark’s full report on VIR stock, click here.

More about Vir Biotechnology

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on infectious diseases and oncology, developing monoclonal antibodies, small interfering RNA therapies and PRO-XTEN-masked T-cell engagers targeting conditions such as chronic hepatitis delta and solid tumors including prostate, HER2-expressing and EGFR-expressing cancers. The company uses proprietary discovery platforms, including its dAIsY artificial intelligence engine and PRO-XTEN masking technology, to engineer next-generation immunotherapies for global markets, retaining key commercialization rights while selectively out-licensing regional rights.

Average Trading Volume: 1,661,196

Technical Sentiment Signal: Sell

Current Market Cap: $827.8M

For a thorough assessment of VIR stock, go to TipRanks’ Stock Analysis page.